Novo Nordisk and Omeros reach asset purchase and licensing agreement for zaltinibart
October 16, 2025
Source: drugdu
77
On October 15, Novo NordiskNovo Nordisk and Omeros announced a definitive asset purchase and license agreement for zaltinibart (OMS906), a clinical-stage drug candidate for the treatment of rare blood and kidney diseases. Under the terms of the agreement, Novo Nordisk will obtain exclusive development and commercialization rights for zaltinibart for all indications worldwide. Omeros is eligible to receive an upfront payment of US$340 million and near-term milestone payments, with a total of up to US$2.1 billion including potential development and commercial milestones, plus tiered royalties based on net sales. The transaction is expected to close in the fourth quarter of 2025.
https://finance.eastmoney.com/a/202510153535182876.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
